RxDoctor Payments Data

Nicolas Shammas, MD

Interventional Cardiology · Davenport, IANPI 1922087857

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $665,338 of the $808,016 with a category attached, or 82.3%. It is spread thinly across 45 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2019 at $222,024 and has fallen 74.6% since, to $56,426 in 2025. Among interventional cardiology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$808,016in general payments, 2019–2025

Across 691 payments — averaging $1169.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$189K
  • Boehringer Ingelheim$130K
  • Lilly USA, LLC$92K
  • Bayer$85K
  • Merck$60K
  • Amgen$42K
  • plus $209K from 39 others
$4,217,787in research payments, 2019–2025

Across 269 payments — averaging $15,680 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$1.6M
  • Shockwave Medical, Inc$649K
  • Angiodynamics, Inc.$626K
  • Amgen$441K
  • Bard Peripheral Vascular, Inc.$300K
  • Philips North America LLC$123K
  • plus $440K from 11 others

What the payments were for

  • Consulting fees$80,12310%
  • Speaking & faculty fees$665,33882%
  • Grants$270%
  • Travel & lodging$45,8316%
  • Food & beverage$16,3832%
  • Education$3140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808,016 in reported general payments places this provider in the 95th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$625,288
Medicare patients
1,774
Services billed
4,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban438$435,795
XareltoRivaroxaban268$324,124
JardianceEmpagliflozin168$158,129
EntrestoSacubitril/Valsartan69$81,410
Repatha SureclickEvolocumab49$43,503
KerendiaFinerenone25$40,038
FarxigaDapagliflozin Propanediol17$18,431
BrilintaTicagrelor20$18,290
OzempicSemaglutide11$8,941
Metoprolol Succinate733$8,704
Ezetimibe336$8,135
DapagliflozinDapagliflozin Propanediol11$5,577
Atorvastatin Calcium669$5,377
Cilostazol208$5,006
Isosorbide Mononitrate ErIsosorbide Mononitrate389$4,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$435,795438 claims
Johnson & JohnsonXarelto$189,494$324,124268 claims
Boehringer IngelheimJardiance$130,214$158,129168 claims
NovartisEntresto$33,770$81,41069 claims
BayerKerendia$85,038$40,03825 claims
AstraZenecaFarxiga, Brilinta$1,215$36,72137 claims
Novo NordiskOzempic$164$8,94111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →